Canaccord upgraded Mayne Pharma to Buy from Hold with a price target of A$6.69, up from A$3.80, after the company released its first half results. Positive trends across all segments are continuing and new management is well proving its ability to execute and to restore investor confidence in the longer-term sustainable growth story, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>